Welcome to our dedicated page for Immutep American Depositary Shares news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep American Depositary Shares stock.
Immutep Limited (NASDAQ: IMMP) is a globally active biotechnology company focusing on the development of innovative immunotherapy products for cancer and autoimmune diseases. Listed on both the Australian Stock Exchange and the Nasdaq Global Market in the U.S., Immutep is at the forefront of personalized bio-therapeutic treatment options.
At the core of Immutep's research and development is the LAG-3 immune control mechanism, crucial for the regulation of the T cell immune response. The company's flagship product, IMP321, a T cell immunostimulatory factor (APC activator), has completed Phase II clinical trials for cancer chemo-immunotherapy. This product is designed to enhance the body's immune response to cancer, providing a novel treatment option for patients.
In addition to IMP321, Immutep is advancing several other LAG-3 related products. These include IMP701, a blocking anti-LAG-3 antibody for cancer currently in Phase I clinical trials, and CVac, a personalized immunocellular therapeutic being investigated for the treatment of epithelial cancer. The development of these products is supported through partnerships with large pharmaceutical companies, aiming to accelerate the availability of these innovative treatments.
Immutep's operations are headquartered in Australia, with the majority of its revenue derived from product sales. The company remains committed to maximizing shareholder value through its technological expertise and robust pipeline of products.
For investors, Immutep represents a significant opportunity in the biotechnology sector, with its cutting-edge research and promising clinical advancements poised to make a substantial impact on cancer and autoimmune disease treatment.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has made significant advancements in its clinical development strategy for the quarter ending March 31, 2023. The company initiated the AIPAC-003 Phase II/III trial for eftilagimod alpha (efti) in HER2-negative and triple-negative metastatic breast cancer, with the first patient enrollment expected in Q2 2023. Positive final data from the TACTI-002 trial showed a 39% overall survival rate at 21 months for patients with second-line non-small cell lung cancer (NSCLC). The TACTI-003 trial reached 75% enrollment, and top-line results are anticipated in H2 2023. Furthermore, the INSIGHT-003 trial's expansion aims to evaluate a triple combination therapy in NSCLC. Immutep maintains a robust cash position of A$55.2 million, providing a runway until June 2024.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the presentation of final results from the Phase II TACTI-002 trial, focusing on patients with second-line head and neck squamous cell carcinoma. The results will be showcased at the 2023 ASCO Annual Meeting, which takes place from June 2-6 in Chicago, Illinois. The trial evaluates the combination of eftilagimod alpha and pembrolizumab in patients who are unselected for PD-L1 expression. Additionally, the trial design for the Phase II/III AIPAC-003 study, which tests eftilagimod alpha in HER2-negative metastatic breast cancer, will also be presented. Key presentation details include poster sessions on June 4 and 5. This opportunity allows Immutep to engage with leading oncology experts and gain visibility for its innovative therapies.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has appointed Florian D. Vogl, M.D., Ph.D., MSc, as its new Chief Medical Officer, effective May 1, 2023. Dr. Vogl brings over a decade of biopharmaceutical experience, particularly in oncology, having previously served as CMO at Cellestia Biotech and held senior roles at Rainier Therapeutics, Novartis, and Amgen. He is recognized for his expertise in clinical strategy and regulatory affairs in both the U.S. and Europe. Dr. Vogl succeeds Frédéric Triebel, who will now focus solely on his role as Chief Scientific Officer. Immutep aims to advance its late-stage clinical pipeline in oncology and its pre-clinical program in autoimmune diseases under Dr. Vogl's leadership. The company is known for its LAG-3 immunotherapy portfolio, including the promising candidate, eftilagimod alpha, which has shown encouraging efficacy and safety in treating various solid tumors.
FAQ
What is the current stock price of Immutep American Depositary Shares (IMMP)?
What is the market cap of Immutep American Depositary Shares (IMMP)?
What is Immutep Limited?
What products does Immutep specialize in?
What is the LAG-3 immune control mechanism?
What is IMP321?
What are the other key products in Immutep's pipeline?
With which markets is Immutep affiliated?
Where is Immutep headquartered?
What are Immutep's key partnerships?
How does Immutep generate revenue?
Why should investors consider Immutep?
